English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
हिन्दी
日本語
By Ben Glickman
Ventyx Biosciences will terminate two trials of its inflammation treatment after efficacy results were below expectations.
The San Diego-based company, which is developing treatments for inflammatory diseases, said that a Phase 2 trial of VTX958 in treatment of moderate to severe plaque psoriasis met its primary and key secondary endpoints, but did not reach the company’s internal target for efficacy.
Ventyx said it will no longer develop VTX958 for treating plaque psoriasis and will stop its Phase 2 trial of VTX958 in psoriatic arthritis.
The company will continue to enroll patients in its Phase 2 trial evaluating the drug to treat Crohn’s disease and will conduct an interim efficacy analysis in the first quarter of 2024.
The company said its cash position as of Sept. 30 was $300.8 million.
Write to Ben Glickman at [email protected]
Read the full article here